Drugs that contain Aripiprazole

1. List of Abilify drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(1 year, 12 days ago)

US8642600 OTSUKA Method of treating autism
Jan, 2022

(1 year, 12 days ago)

US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(1 year, 12 days ago)

US6977257 OTSUKA Aripiprazole oral solution
Apr, 2022

(9 months ago)

US8642600

(Pediatric)

OTSUKA Method of treating autism
Jul, 2022

(6 months ago)

US6977257

(Pediatric)

OTSUKA Aripiprazole oral solution
Oct, 2022

(3 months ago)

US8642760

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(a month from now)

US8580796

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(a month from now)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(10 months from now)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(1 year, 4 months from now)

US7550445 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(1 year, 5 months from now)

US7115587 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(1 year, 5 months from now)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Dec, 2024

(1 year, 10 months from now)

US7115587

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(1 year, 11 months from now)

US7550445

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(1 year, 11 months from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(3 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(4 years from now)

Market Authorisation Date: 07 June, 2006

Treatment: Treatment of schizophrenia; Treatment of irritability associated with autistic disorder; Treatment of major depressive disorder (mdd); Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of ABILIFY before it's patent expiration?
More Information on Dosage

ABILIFY family patents

68

United States

38

China

19

Hong Kong

14

European Union

13

Japan

13

Canada

12

Poland

12

Norway

10

Ukraine

10

Spain

10

Argentina

10

Portugal

10

Denmark

9

Cyprus

8

Austria

7

Korea, Republic of

7

Germany

7

Slovenia

7

Russia

7

Taiwan, Province of China

6

Israel

6

Georgia

5

Brazil

5

Australia

5

Malaysia

5

Mexico

5

South Africa

5

Peru

5

New Zealand

3

Hungary

3

Ecuador

2

Lithuania

2

Yugoslavia

2

Croatia

2

Iceland

1

Estonia

1

Chile

1

Uruguay

1

Slovakia

1

Colombia

1

Singapore

1

Bulgaria

1

Philippines

1

Czech Republic

2. List of Abilify Maintena Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8993761 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089567 OTSUKA PHARM CO LTD Method of treating cognitive impairments and schizophrenias
Jan, 2022

(1 year, 12 days ago)

US8759351 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(5 months from now)

US8338428 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(5 months from now)

US8030313 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(1 year, 8 months from now)

US7807680 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(1 year, 8 months from now)

US8722679 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(1 year, 8 months from now)

US8338427 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Mar, 2025

(2 years from now)

US11400087 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(10 years from now)

US11344547 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(10 years from now)

US10980803 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(10 years from now)

US11154553 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(10 years from now)

US10525057 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Mar, 2034

(11 years from now)

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Maintenance monotherapy treatment of bipolar i disorder; Maintenance monotherapy treatment of bipolar 1 disorder

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

69

United States

31

China

16

Hong Kong

11

Japan

11

Norway

10

Poland

10

Canada

10

European Union

8

Spain

8

Portugal

8

Denmark

7

Austria

7

Ukraine

7

Cyprus

7

Slovenia

7

Argentina

6

Germany

4

Israel

4

Taiwan, Province of China

3

Korea, Republic of

3

Australia

3

Mexico

3

South Africa

3

Russia

3

Peru

3

Ecuador

2

Brazil

2

Malaysia

2

Georgia

2

New Zealand

1

Sweden

1

Chile

1

Lithuania

1

Luxembourg

1

Hungary

1

Colombia

1

Croatia

1

Philippines

3. List of Abilify Mycite Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(1 year, 12 days ago)

US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(1 year, 12 days ago)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(10 months from now)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(1 year, 4 months from now)

US11476952 OTSUKA Pharma-informatics system
Apr, 2026

(3 years from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(3 years from now)

US7978064 OTSUKA Communication system with partial power source
Sep, 2026

(3 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(4 years from now)

US9444503 OTSUKA Active signal processing personal health signal receivers
Nov, 2027

(4 years from now)

US9119554 OTSUKA Pharma-informatics system
Dec, 2028

(5 years from now)

US9258035 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(6 years from now)

US9060708 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Mar, 2029

(6 years from now)

US8674825 OTSUKA Pharma-informatics system
Apr, 2029

(6 years from now)

US8956288 OTSUKA In-body power source having high surface area electrode
Jul, 2029

(6 years from now)

US10441194 OTSUKA Ingestible event marker systems
Jul, 2029

(6 years from now)

US8945005 OTSUKA Controlled activation ingestible identifier
Aug, 2029

(6 years from now)

US9433371 OTSUKA In-body device with virtual dipole signal amplification
Sep, 2029

(6 years from now)

US8718193 OTSUKA Active signal processing personal health signal receivers
Dec, 2029

(6 years from now)

US9149577 OTSUKA Body-associated receiver and method
Dec, 2029

(6 years from now)

US8847766 OTSUKA Pharma-informatics system
Mar, 2030

(7 years from now)

US8545402 OTSUKA Highly reliable ingestible event markers and methods for using the same
Apr, 2030

(7 years from now)

US8114021 OTSUKA Body-associated receiver and method
Jun, 2030

(7 years from now)

US11464423 OTSUKA In-body power source having high surface area electrode
Sep, 2030

(7 years from now)

US9941931 OTSUKA System for supply chain management
Nov, 2030

(7 years from now)

US8961412 OTSUKA In-body device with virtual dipole signal amplification
Nov, 2030

(7 years from now)

US8258962 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Nov, 2030

(7 years from now)

US8547248 OTSUKA Implantable zero-wire communications system
Dec, 2030

(7 years from now)

US11229378 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jul, 2031

(8 years from now)

US9320455 OTSUKA Highly reliable ingestible event markers and methods for using the same
Dec, 2031

(8 years from now)

US10517507 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jun, 2032

(9 years from now)

US9268909 OTSUKA Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
Oct, 2033

(10 years from now)

Market Authorisation Date: 13 November, 2017

Treatment: Treatment of schizophrenia; Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a receiver to receive a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver; Method of using a logic circuit to stabilize battery voltage supplied to a sensor embedded with a tablet and that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

219

United States

61

Japan

58

China

46

European Union

34

Canada

32

Israel

30

Hong Kong

26

Korea, Republic of

26

Taiwan, Province of China

18

Australia

18

Denmark

17

Spain

14

Brazil

14

Malaysia

14

Singapore

13

Ukraine

12

Mexico

12

Portugal

11

Poland

11

South Africa

11

Russia

10

Norway

8

Cyprus

7

Slovenia

7

Argentina

6

Austria

6

Germany

5

New Zealand

4

Georgia

4

Peru

4

India

4

Ecuador

3

Chile

2

Lithuania

2

Hungary

2

Philippines

1

Morocco

1

Finland

1

Tunisia

1

Colombia

1

EA

1

Costa Rica

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic